Medical Research
(H30)
IRS Verified
DX Registered
990 on File
CANCER RESEARCH AMERICA NFCR INC
Financial strength (30%)
74/100
Reliability (20%)
50/100
Effectiveness (25%)
71/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Mission Statement
The National Foundation for Cancer Research (NFCR) was founded in 1973 to support cancer research and public education relating to the prevention, early diagnosis, better treatments and ultimately, a cure for cancer. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. NFCR is committed to Research for a Cure – cures for all types of cancers.
Financial Overview — FY 2024
$11.1M
Total Revenue
$9.8M
Total Expenses
N/A
Net Assets
15
Employees
Program Expense Ratio
N/A
Fundraising Efficiency
0.0%
Operating Reserve
N/A
Liability-to-Asset
24.5%
Revenue Diversification
N/A
Executive Compensation
$0
Compared with Peers
FY 2023
Compared with 479 similar organizations
(United States, Medical Research, $1M–$10M in expenses), FY 2023.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
73.4% | 82.4% |
P10P90
|
Below median |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
8.6% | 11.9% |
P10P90
|
Above median |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
18.0% | 1.0% |
P10P90
|
Bottom quarter |
|
Fundraising efficiency
Fundraising expenses / gross fundraising income
· lower is better
|
3842.8% | 134.1% |
P10P90
|
Bottom quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
9.4 mo | 14.9 mo |
P10P90
|
Below median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
27.1% | 11.5% |
P10P90
|
Below median |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
94.8% | 93.1% |
P10P90
|
Below median |
|
Revenue growth
Year over year revenue growth
|
9.0% | 7.0% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
15.4% | 12.8% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
-6.9% | 0.2% |
P10P90
|
Impact
1 program| Outcome / Program | People Served | Cost / Service | # Completed | Duration |
|---|---|---|---|---|
| educate public and fund scientific cancer researchers | 18,000,000 | $9,500,000.00 | — | Per Year |
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $11.1M | $9.8M | N/A | — | 15 |
| 2023 | $9.2M | $9.8M | $7.7M | 73.4% | 16 |
| 2022 | $8.4M | $8.5M | $7.6M | 72.4% | 16 |
| 2021 | $10.1M | $10.2M | N/A | — | 23 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.